We are live on ! Find out more
SNOA icon

Sonoma Pharmaceuticals
SNOA

17 hedge funds and large institutions have $574K invested in Sonoma Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% more ownership

Funds ownership: 0.28% → 0.3% (+0.02%)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

6% less funds holding

Funds holding: 18 → 17 (-1)

21% less capital invested

Capital invested by funds: $726K → $574K (-$152K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$82.2K
2
Renaissance Technologies
Renaissance Technologies
New York
+$49.3K
3
Bank of America
Bank of America
North Carolina
+$23.6K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$20.6K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$153K
2
UBS Group
UBS Group
Switzerland
-$9.8K
3
TRCT
Tower Research Capital (TRC)
New York
-$2.69K
4
Morgan Stanley
Morgan Stanley
New York
-$64

SNOA Hedge Fund Activity: Q2 2022 in Review

17 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2022, worth a combined $574K — down 21% from $726K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of SNOA and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $82.2K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $153K sold.

  • 17 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2022, down from 18 in Q1 2022.
  • Funds reported $574K of Sonoma Pharmaceuticals stock for Q2 2022, down 21% quarter-over-quarter.
  • 1 fund opened new Sonoma Pharmaceuticals positions in Q2 2022 and 2 closed out, a net change of -1 holder.
  • The largest Sonoma Pharmaceuticals buyer in Q2 2022 was Citadel Advisors, an estimated $82.2K added.
  • The largest Sonoma Pharmaceuticals seller in Q2 2022 was Two Sigma Securities, an estimated $153K sold.

Based on aggregated 13F filings for Q2 2022.